Adding AKT Inhibitor Shows Benefit in PTEN-Deficient Prostate Cancer
The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer in the phase III CAPItello-281 study presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. In this exclusive MedPage Today video, Daniel J. George,…
